---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-278679"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:24:46.792716+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences prices 9.7M share offering at $31 and $230M 1.625% convertible notes due 2031 for ~$475M net

## Summary
- Equity offering of 9,677,420 shares at $31.00 per share, upsized from $200M, with underwriters exercising over-allotment for additional 1,451,613 shares.
- Convertible notes offering of $200M aggregate principal (upsized to $230M) of 1.625% senior notes due 2031, conversion premium ~45% above equity offering price.
- Combined net proceeds expected ~$475.3M, to be used to repay $50M term loan and fund development/commercialization of bezuclastinib.
- Offerings led by J.P. Morgan, Jefferies, Leerink Partners, and Guggenheim Securities for equity; Jefferies and J.P. Morgan for notes.

## SEC filing metadata
- accession: 0001193125-25-278679
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312525278679/0001193125-25-278679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312525278679/d46097d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-278679
- JSON: https://secwatch.observer/filing/0001193125-25-278679.json
- Plain text: https://secwatch.observer/filing/0001193125-25-278679.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.